ALVR Allovir Inc
Allovir Inc Latest News
About Allovir Inc
AlloVir is an American healthcare company and is one of the leading names around the globe in the development of Virus-Specific T-cell (VST) immunotherapies. Founded in 2013 and headquartered in Cambridge, Massachusetts, the firm is focussed on developing highly innovative, allogeneic, off-the-shelf VST therapy candidates which target twelve devastating viral infections with both treatment and prevention. The firm’s work is aimed at helping patients with T-cell deficiencies, many of whom currently have limited treatment options or no viable treatment at all. The company launched publicly in 2020 with an upsized IPO that raised $276.25m. Allovir is listed on the NASDAQ GS and trades its stock under the ticker ALVR. In November 2020 the ALVR share price was $34.55 and the company had a market cap of $2.13bn. The company’s platform is highly efficient, practising advanced VST profiling and antigen selection to induce the strongest T-cell immune responses. Their CytokinTM donor selection process ensures an efficient selection of carefully-screened donors. The firm maintains a pipeline of therapeutic candidates in pre-clinical and clinical trials targeting high-risk individuals, such as organ transplant patients and those suffering various chronic illnesses. Add ALVR stock to your eToro watchlist to get news and updates on this instrument.Show More
Waltham, Massachusetts, US
Diana M. Brainard, MD
Allovir Inc Q4 2022 earnings report is expected to be released before market open
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.